Who are Oxaliplatin, calcium folinate, 5-fluorouracil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxaliplatin-calcium-folinate-5-fluorouracil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Oxaliplatin, calcium folinate, 5-fluorouracil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxaliplatin, calcium folinate, 5-fluorouracil (Oxaliplatin, calcium folinate, 5-fluorouracil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy combination (FOLFOX regimen). Area: Oncology.

phase 3 Platinum-based chemotherapy combination (FOLFOX regimen) DNA (oxaliplatin); thymidylate synthase (5-fluorouracil) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Oxaliplatin, calcium folinate, 5-fluorouracil (Oxaliplatin, calcium folinate, 5-fluorouracil) — Karolinska University Hospital. This combination chemotherapy regimen kills cancer cells by damaging DNA and inhibiting nucleotide synthesis, with oxaliplatin forming platinum-DNA adducts, 5-fluorouracil inhibiting thymidylate synthase, and calcium folinate enhancing 5-FU efficacy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxaliplatin, calcium folinate, 5-fluorouracil TARGET	Oxaliplatin, calcium folinate, 5-fluorouracil	Karolinska University Hospital	phase 3	Platinum-based chemotherapy combination (FOLFOX regimen)	DNA (oxaliplatin); thymidylate synthase (5-fluorouracil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy combination (FOLFOX regimen) class)

Karolinska University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxaliplatin, calcium folinate, 5-fluorouracil — Competitive Intelligence Brief. https://druglandscape.com/ci/oxaliplatin-calcium-folinate-5-fluorouracil. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab